The work is published in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common ...

Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a ...

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

B-cell Acute Lymphoblastic Leukaemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of paediatric cancer cases ...

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases ...

Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

Researchers show that glycoRNAs, uncovered by the lab of Nobel Laureate, Carolyn Bertozzi, can be used to fight cancer.

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to ...

American pharmaceutical company AbbVie has marked its entry into the Indian cancer drugs segment with Venetoclax used to ...

They investigated how cancer affects the energy management of a patient's T cells and showed for the first time that contact ...